Comparative Pharmacology
Head-to-head clinical analysis: CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER versus FORTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER versus FORTAZ.
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER vs FORTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefotetan is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in cell lysis and death.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
1 to 2 g intravenously every 12 hours for 5 to 10 days. For severe infections, 2 g intravenously every 12 hours.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
None Documented
None Documented
Terminal elimination half-life 3-4 hours in normal renal function; prolonged in renal impairment (e.g., up to 13 hours in severe renal failure).
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
Primarily renal (unchanged drug) ~88%; minor biliary/fecal ~6-9%.
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic